Skip to main content
Log in

Keynote Webinar | Spotlight on Cardio-Oncology

Register now for the free live webinar 

Tuesday 16th May, 17:30-19:00 (CEST)



You must have an account and be logged in to register for this webinar. 
(No account yet? Register here for free) 

In this 90-minute live webinar on cardio-oncology, a leading panel of international experts will discuss:

  • New ESC guidelines on cardio-oncology, highlighting the most clinically relevant recommendations such as cardiovascular toxicity definitions, cardiovascular toxicity risk stratification strategies and preventive strategies in cardio-oncology;
  • The pathophysiology, incidence, risk stratification, therapy and clinical management of myocarditis as an adverse effect seen with immune checkpoint inhibitors (a class of drugs frequently used in cancer treatment);
  • The role of biomarkers in the follow-up of patients receiving antineoplastic agents and in guiding cardiovascular treatment in cancer patients.

Between the lectures, as well as during the panel discussion, you will have the opportunity to pose questions directly to each speaker or to the panel of experts as a whole. 
 

Log in and register

About this webinar

Agenda

What we should all know about ESC guidelines on cardio-oncology 
Dr. Teresa López Fernández 

Immune checkpoint inhibitor-associated myocarditis 
Prof. Lorenz Lehmann

Biomarkers in cardio-oncology 
Prof. Rudolf de Boer  

Panel discussion with all experts  

Faculty

Prof. Rudolf de Boer
Prof. Lorenz Lehmann
Dr. Teresa Lopéz Fernández

Learning objectives & accreditation

After participating in this program, learners will be able to: 

  • Apply the new ESC cardio-oncology guidelines to treatment of cancer patients with cardiovascular risks 
  • Identify and appraise the risks of cardiological outcomes in patients receiving immune-checkpoint inhibitor therapy 
  • Identify and utilise biomarkers as part of long-term follow-up of cardiovascular risks in cancer patients

An application has been made to the UEMS EACCME® for CME accreditation of this event.

Faculty disclosures

Prof. Rudolf de Boer

Clinical Cardiologist and Professor of Translational Cardiology at the University Medical Center Groningen, The Netherlands.

Prof. de Boer is a Clinical Cardiologist, a Professor of Translational Cardiology, and the Director of the Experimental Cardiology at the University Medical Center Groningen, the Netherlands. 
 

Disclosures

  • Grant/research support: AstraZeneca, Abbott, Boehringer Ingelheim, Cardio Pharmaceuticals GmbH, Ionis Pharmaceuticals Inc, Novo Nordisk, Roche
  • Speaker’s Bureau: Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, Roche

Dr. Teresa López Fernández

Consultant Cardiologist, University Hospital La Paz, Madrid, Spain

Dr. López Fernández leads the Cardio-Oncology Unit at University Hospital La Paz, Madrid, where she specializes in cardiac imaging. 
 

 Disclosures

  • Honoraria/consultation fees: Philips, Myocardial Solutions
  • Speaker’s Bureau: Janssen, Daiichi Sankyo, AstraZeneca, Beigene

Prof. Lorenz Lehmann

Professor of Cardiology, Heidelberg University Hospital, Heidelberg, Germany

Prof. Lorenz Lehmann is a Clinical Cardiologist, a Professor of Cardiology and the Head of the Institute of Cardio-Oncology as well as the Special Outpatient Clinic for Cardio-Oncology at the Heidelberg University Hospital. 
 

Disclosures

  • Honoraria/consultation fees: Daiichi Sankyo, Senaca, AstraZeneca, Servier
  • Speaker’s Bureau: Novartis, MSD

Moderators

Dr. Jane Godsland

Clinical Director, Springer Medicine, Springer Healthcare, London, United Kingdom 
 

Disclosures

  • No disclosure to declare

Dr. Erik Heintz

Editor-in-Chief SpringerMedizin.de, Springer Medizin Verlag GmbH, Munich, Germany 
 

Disclosures

  • No disclosure to declare

 Log in and register
Webinar ID and Frequently Asked Questions
Image Credits